Lymphoma patients at high risk of infections after diagnosis | Uppsala University ⁦@UU_University⁩

RT @michaelwangmd: Results from our phase 3 SYMPATICO trial of ibrutinib plus venetoclax in R/R MCL show that the combination improved PFS…

RT @DavidSteensma: When reports emerged in 2023 of T cell secondary malignancies in CAR-T treated pts, mechanism was unclear. New MSKCC re…

RT @VJHemOnc: #ASH24 | @glimelius (@UU_University) discusses the safety and efficacy of zilovertamab vedotin in R/R #MantleCellLymphoma pos…

@BijoyTelivala Rare

@epikrisa @sahlgrenska Hur det kan leda till roligare jobb i framtiden (delad klinik/ forskning), att det ”krävs” för att bli ÖL ibland, berätta hur man börjar, berätta om din väg in men att det finns andra också. Att man kan hämta på dagis, gå till tandläkaren etc på dagtid forsk ger tidsflexibilitet

Se den 👌

RT @BloodCancerTalk: Our first post-#ASH24 episode just dropped! Lymphoma and CLL highlights with @dgermain21! We discuss: TRIANGLE ENRICH…

RT @SanofiMyeloma: See why achieving minimal residual disease negativity (MRD-) can be predictive of improved outcomes in #MultipleMyeloma…

And now I can not sleep… jet lag

RT @AaronGoodman33: Very proud of our UCSD BMT fellow graduate. Also interesting data on delayed neurotoxicity which is quite nasty for pat…

RT @DrRaulCordoba: #ASH24 Atrial Fibrillation Management and Outcomes in Bruton's Tyrosine Kinase Inhibitor Treated Chronic Lymphocytic Leu…

#ASH24 highlights Jennifer Tovbridge - CLL first line, #AMPLIFY, favors Acala+Ven+ Obi vs chemo and Acala + Ven - MCL first line #ENRICH favored R-Ibrutinib over R-Chema (I am very proud 4th author 😊 and responsible in Sweden) - RWD on CAR-T in transformed indolentNHL=good!

LBA-6 #MCL #ASH24. US-study, role of ASCT in MCL in abscense of BTKi. Randomize if MRD- after induction with clonoSeq, peripheral blood. - no sign difference between patients treated with ASCT+ Rituximab versus only rituximab maintenance if MRD- ➡️ ASCT Not needed! - MRD positive patients benefit from ASCT!

@calliecoombsmd @graham74GC Interesting to here also others with this experience

@sciqst @graham74GC Yes, aplastic anemia very unexpected. Started with liver tox, followed by ”maybe” immune-mediated pancytopenia. Please see details here: Anna Nikkarienen E J Haematol 2024

RT @VJHemOnc: Fresh updates from #ASH24 with @glimelius (@UU_University)! ⭐Zilovertamab vedotin shows promise for relapsed/refractory #Man…

Amazing educational session on Follicular lymphoma @WomeInLymphoma - shift perspective: stop saying to patients it is incurable, we see ”functional cure” - POD24: how do we identify? Tro to find predictive markers! - Bispecifics or CAR-t: advantages with both, higher CR rates with CAR, but bispecific available only on some countries - ”TMV: looks nice in a curve but unusable in clinical care”